1-7 of 7
Olli Kallioniemi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Anagrelide for Gastrointestinal Stromal Tumor

Olli-Pekka Pulkka, Yemarshet K. Gebreyohannes, Agnieszka Wozniak, John-Patrick Mpindi, Olli Tynninen, Katherine Icay, Alejandra Cervera, Salla Keskitalo, Astrid Murumägi, Evgeny Kulesskiy, Maria Laaksonen, Krister Wennerberg, Markku Varjosalo, Pirjo Laakkonen, Rainer Lehtonen, Sampsa Hautaniemi, Olli Kallioniemi, Patrick Schöffski, Harri Sihto, Heikki Joensuu
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (5): 1676–1687.
https://doi.org/10.1158/1078-0432.CCR-18-0815
Published: 01 March 2019
View article titled, Anagrelide for Gastrointestinal Stromal Tumor
Open the PDF for Anagrelide for Gastrointestinal Stromal Tumor in another window
Includes: Supplementary data
Journal Articles

Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies

Anita Sveen, Jarle Bruun, Peter W. Eide, Ina A. Eilertsen, Lorena Ramirez, Astrid Murumägi, Mariliina Arjama, Stine A. Danielsen, Kushtrim Kryeziu, Elena Elez, Josep Tabernero, Justin Guinney, Hector G. Palmer, Arild Nesbakken, Olli Kallioniemi, Rodrigo Dienstmann, Ragnhild A. Lothe
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (4): 794–806.
https://doi.org/10.1158/1078-0432.CCR-17-1234
Published: 14 February 2018
View article titled, Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies
Open the PDF for Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies in another window
Includes: Supplementary data
Journal Articles

Abstract POSTER-TECH-1111: High-throughput drug sensitivity and resistance testing of ovarian cancer cell lines provides useful strategy for assessing drug repositioning and therapeutic possibilities of emerging drugs

Akira Hirasawa, Astrid Murumägi, Mariliina Arjama, Bhagwan Yadav, John Patrick Mpindi, Krister Wennerberg, Tero Aittokallio, Daisuke Aoki, Olli Kallioniemi
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (16_Supplement): POSTER-TECH-1111.
https://doi.org/10.1158/1557-3265.OVCASYMP14-POSTER-TECH-1111
Published: 15 August 2015
View article titled, Abstract POSTER-TECH-1111: High-throughput drug sensitivity and resistance testing of ovarian cancer cell lines provides useful strategy for assessing drug repositioning and therapeutic possibilities of emerging drugs
Journal Articles

Abstract A34: Development of a drug sensitivity testing pipeline towards the establishment of precision medicine for ovarian cancer

Akira Hirasawa, Astrid Murumägi, Bhagwan Yadav, John Patrick Mpindi, Arjama Mariliina, Tero Aittokallio, Krister Wennerberg, Daisuke Aoki, Olli Kallioniemi
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (19_Supplement): A34.
https://doi.org/10.1158/1078-0432.OVCA13-A34
Published: 13 May 2014
View article titled, Abstract A34: Development of a drug sensitivity testing pipeline towards the establishment of precision medicine for ovarian cancer
Journal Articles

Mammary-Derived Growth Inhibitor Alters Traffic of EGFR and Induces a Novel Form of Cetuximab Resistance

Jonna Nevo, Elina Mattila, Teijo Pellinen, Daniel L. Yamamoto, Henri Sara, Kristiina Iljin, Olli Kallioniemi, Petri Bono, Päivi Heikkilä, Heikki Joensuu, Anni Wärri, Johanna Ivaska
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (21): 6570–6581.
https://doi.org/10.1158/1078-0432.CCR-09-0773
Published: 02 November 2009
View article titled, Mammary-Derived Growth Inhibitor Alters Traffic of EGFR and Induces a Novel Form of Cetuximab Resistance
Open the PDF for Mammary-Derived Growth Inhibitor Alters Traffic of EGFR and Induces a Novel Form of Cetuximab Resistance in another window
Includes: Supplementary data
Journal Articles

High-Throughput Cell-Based Screening of 4910 Known Drugs and Drug-like Small Molecules Identifies Disulfiram as an Inhibitor of Prostate Cancer Cell Growth

Kristiina Iljin, Kirsi Ketola, Paula Vainio, Pasi Halonen, Pekka Kohonen, Vidal Fey, Roland C. Grafström, Merja Perälä, Olli Kallioniemi
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (19): 6070–6078.
https://doi.org/10.1158/1078-0432.CCR-09-1035
Published: 30 September 2009
View article titled, High-Throughput Cell-Based Screening of 4910 Known Drugs and Drug-like Small Molecules Identifies Disulfiram as an Inhibitor of Prostate Cancer Cell Growth
Open the PDF for High-Throughput Cell-Based Screening of 4910 Known Drugs and Drug-like Small Molecules Identifies Disulfiram as an Inhibitor of Prostate Cancer Cell Growth in another window
Includes: Supplementary data
Journal Articles

CIP2A Is Associated with Human Breast Cancer Aggressivity

Christophe Côme, Anni Laine, Maïa Chanrion, Henrik Edgren, Elina Mattila, Xiaoling Liu, Jos Jonkers, Johanna Ivaska, Jorma Isola, Jean-Marie Darbon, Olli Kallioniemi, Simon Thézenas, Jukka Westermarck
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (16): 5092–5100.
https://doi.org/10.1158/1078-0432.CCR-08-3283
Published: 12 August 2009
View article titled, CIP2A Is Associated with Human Breast Cancer Aggressivity
Open the PDF for CIP2A Is Associated with Human Breast Cancer Aggressivity in another window
Includes: Supplementary data